Biotech | 17 August 2021
Indian pharma’s vaccine opportunity at US $ 10-11 billion
Domestic market and developing countries will need doses of Indian vaccines
Domestic market and developing countries will need doses of Indian vaccines
This is the first of its kind vaccine for Covid 19 to get the go-ahead
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The collaboration will support Canada with direct access to rapid pandemic response capabilities
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Company working on COVID vaccine INO 4800
Deal signed with AOP Orphan for US commercial rights
A veteran in cell therapy and oncology commercialisation
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Filing for WHO Emergency Use Authorisation this month
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Board declares interim dividend of Rs 2 per equity share
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
Advances deployment of mRNA technology across vaccines and therapeutics development
Subscribe To Our Newsletter & Stay Updated
